Pacific Biosciences said it will collaborate with the n‑Lorem Foundation and EspeRare to study individualized antisense oligonucleotide (ASO) therapies, deploying PacBio HiFi long‑read whole‑genome sequencing to support design and molecular characterization. PacBio also reported preliminary Q4 revenues up ~14% and full‑year 2025 revenue modestly higher, driven by instrument placements and record consumables sales. The collaboration pairs PacBio’s long‑read sequencing with patient‑specific therapeutic design efforts, a growing model for rare disease personalized medicine that leverages high‑accuracy genome assemblies for ASO target selection and validation.